Drug Profile
Insulin aspart - Novo Nordisk
Alternative Names: Asp-B28; NovoLog; NovoRapidLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gestational diabetes; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 06 Nov 2023 Efficacy data from a phase III trial in Type 2 diabetes mellitus and Type 1 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 19 Oct 2020 Novo Nordisk plans a phase III trial for Type 2 diabetes mellitus and Type 1 diabetes mellitus (Combination therapy) in China (SC) (NCT04588259)
- 09 Oct 2020 Novo Nordisk initiates enrolment in a phase III trial for Type 2 diabetes mellitus and Type 1 diabetes mellitus (Combination therapy) in China (SC) (NCT04588259)